Perseus Proteomics Inc
TSE:4882

Watchlist Manager
Perseus Proteomics Inc Logo
Perseus Proteomics Inc
TSE:4882
Watchlist
Price: 240 JPY 1.69% Market Closed
Market Cap: ¥3.5B

Operating Margin

-665.6%
Current
Improving
by 116%
vs 3-y average of -781.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-665.6%
=
Operating Income
¥-811.7m
/
Revenue
¥121.9m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-665.6%
=
Operating Income
¥-811.7m
/
Revenue
¥121.9m

Peer Comparison

Country Company Market Cap Operating
Margin
JP
Perseus Proteomics Inc
TSE:4882
3.5B JPY
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.9B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
183.6B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.9B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
88.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.7B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 99% of companies in Japan
Percentile
1st
Based on 6 730 companies
1st percentile
-665.6%
Low
-125 500% — 4.2%
Typical Range
4.2% — 10.6%
High
10.6% — 9 743.7%
Distribution Statistics
Japan
Min -125 500%
30th Percentile 4.2%
Median 7%
70th Percentile 10.6%
Max 9 743.7%

Perseus Proteomics Inc
Glance View

Market Cap
3.5B JPY
Industry
Biotechnology

Perseus Proteomics, Inc. is a holding company that develops antibody-based therapeutics and diagnostics. The company is headquartered in Meguro-Ku, Tokyo-To and currently employs 21 full-time employees. The company went IPO on 2021-06-22. The firm is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The firm is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.

Perseus Proteomics Inc Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-665.6%
=
Operating Income
¥-811.7m
/
Revenue
¥121.9m
What is Perseus Proteomics Inc's current Operating Margin?

The current Operating Margin for Perseus Proteomics Inc is -665.6%, which is above its 3-year median of -781.7%.

How has Operating Margin changed over time?

Over the last 3 years, Perseus Proteomics Inc’s Operating Margin has decreased from -592.1% to -665.6%. During this period, it reached a low of -947.3% on Dec 31, 2023 and a high of -592.1% on Sep 30, 2022.

Back to Top